LY-CoV2-derived Anti-SARS-CoV-2 RBD mAbs

Antibody description

InvivoGen provides a set of recombinant monoclonal antibodies (mAbs) featuring a mouse IgG2a constant region, and the variable region of 'Bamlanivimab (LY-CoV555)' or 'Etesevimab (LY-CoV016'),  two clones originally described as potent  SARS-CoV-2 neutralizing mAbs [1,2]:

• Anti-CoV2RBD-bam-mIgG2a (derived from Bamlavinimab)
• Anti-CoV2RBD-ete-mIgG2a (derived from Etesevimab)

InvivoGen's Anti-CoV2RBD-bam-mIgG2a and Anti-CoV2RBD-ete-mIgG2a have been generated by recombinant DNA technology, produced in CHO cells, and purified by affinity chromatography, ensuring lot-to-lot reproducibility. Furthermore, these mAbs have been functionally validated by ELISA (see data below). The absence of bacterial contamination has been confirmed by cellular assays.

Background

Bamlavinimab and Etesevimab (originally named 'clone CB6') were generated using serum from a convalescent patient [1, 2]. These mAbs specifically target two distinct but overlapping regions of the SARS-CoV-2 S-RBD and potently block its binding to the ACE2 receptor on target cells [1, 2]. 

Applications

• Detecting the presence of SARS-CoV-2 in culture supernatant and/or in serum (ELISA)
• Flow cytometry binding assays 
• Developing neutralizing antibody cocktails against SARS-CoV-2
• Monitoring SARS-CoV-2 variant escape

Quality control

Functionally validated by ELISA using coated Spike-RBD proteins derived from SARS-CoV-2 variants

References

1. Jones B.E. et al., 2021. The neutralizing antibody, LY-CoV555, protects against SARS-CoV-2 infection in nonhuman primates. Sci Transl Med 13(593), eabf1906(2021).
2. Shi R. et al., 2020. A human neutralizing antibody targets the receptor-binding site of SARS-CoV-2. Nature. 584:120-124.